Literature DB >> 420716

Connective tissue activation. XIV. Composition and actions of a human platelet autacoid mediator.

C W Castor, J C Ritchie, C H Williams, M E Scott, S L Whitney, S L Myers, T B Sloan, B E Anderson.   

Abstract

Connective tissue activating peptide-III (CTAP-III) isolated from human platelets is a potent mitogen for human connective tissue cells in culture in addition to stimulating glycosaminoglycan synthesis, glucose consumption, and lactate formation. The amino acid composition of apparently homogeneous CTAP-III was determined, confirming the presence of two disulfide links and providing a calculated molecular weight of 11,633 daltons. Comparison of the mitogenic activity of serum and plasma-serum suggests that CTAP-III is a major mitogenic component of human serum. Seventeen strains of human connective tissue cells (synovial, cartilage, dermal and thyroid) incorporated [3H]-thymidine at up to 30 times control at levels under the influence of microgram quantities of CTAP-III and caused detectable increases in thymidine incorporation at levels as low as 10-29 ng/ml. Prostaglandin E1 (0.01 microgram/ml) and dibutyryl cyclic AMP (25 microgram/ml) potentiated the glycosaminoglycan stimulating effect of CTAP-III, but not its mitogenic effect. Cycloheximide and actinomycin D blocked the biologic actions of CTAP-III. Cortisol and penicillamine had little effect on the mitogenic activity of CTAP-III, whereas antirheumatic agents such as acetylsalicylic acid and phenylbutazone opposed the mitogenic activity when added to cultures at clinically relevant concentrations. A weak antiheparin factor secreted by platelets, low affinity platelet factor 4 (LA-PF4), was shown to be similar to CTAP-III in biologic actions, electrophoretic mobility, amino acid composition, and antigenic determinants.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 420716     DOI: 10.1002/art.1780220308

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

1.  Serum contains a platelet-derived transforming growth factor.

Authors:  C B Childs; J A Proper; R F Tucker; H L Moses
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

Review 2.  Cytokines and other mediators in rheumatoid arthritis.

Authors:  J M Dayer; S Demczuk
Journal:  Springer Semin Immunopathol       Date:  1984

3.  Systemic sclerosis: a collagen or microvascular disease?

Authors:  M I Jayson
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-23

4.  Structural and biological characteristics of connective tissue activating peptide (CTAP-III), a major human platelet-derived growth factor.

Authors:  C W Castor; J W Miller; D A Walz
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

5.  Connective tissue activation in guinea pig lung fibroblast cultures: regulatory effects of glucocorticoids.

Authors:  J C Seidman; C W Castor
Journal:  In Vitro       Date:  1981-02

6.  Beta-thromboglobulin in inflammatory synovial fluid.

Authors:  R Hällgren; A Bjelle; P Venge
Journal:  Inflammation       Date:  1983-12       Impact factor: 4.092

7.  Connective tissue activation. XXI. Regulation of glycosaminoglycan metabolism by lymphocyte (CTAP-I) and platelet (CTAP-III) growth factors.

Authors:  C W Castor; M C Bignall; P A Hossler; D J Roberts
Journal:  In Vitro       Date:  1981-09

8.  Raised serum hyaluronate levels in scleroderma: an effect of growth factor induced activation of connective tissue cells?

Authors:  A Engström-Laurent; N Feltelius; R Hällgren; A Wasteson
Journal:  Ann Rheum Dis       Date:  1985-09       Impact factor: 19.103

9.  Platelet serotonin in systemic sclerosis.

Authors:  P S Klimiuk; A Grennan; C Weinkove; M I Jayson
Journal:  Ann Rheum Dis       Date:  1989-07       Impact factor: 19.103

10.  Selective inhibition of thromboxane biosynthesis in human blood mononuclear cells and the effects of mitogen-stimulated lymphocyte proliferation.

Authors:  D Gordon; A M Nouri; R U Thomas
Journal:  Br J Pharmacol       Date:  1981-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.